Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Silence Therapeutics plc
Headquarters: London, United Kingdom
Website: http://www.silence-therapeu...
Year Founded: 1999
Status: Public
Industry Sector: CommercialServices
CEO: Craig Allen Tooman, MBA
Number Of Employees: 116
Enterprise Value: $170,988,100
PE Ratio: -1.64
Exchange/Ticker 1: NASDAQ:SLN
Exchange/Ticker 2: N/A
Latest Market Cap: $129,395,704
BioCentury | Apr 22, 2024
Finance
Delisting biotechs take AIM at U.K. exchange
What three companies’ decisions to delist say about life on the London exchange for development-stage biotechs
BioCentury | Feb 10, 2024
Finance
Public equity report: IPOs for Kyverna, Metagenomi; 4D, Sana among follow-ons
Plus PIPEs for Adverum, Autolus, Mineralys, Silence, PepGen, Sensorion, Tenaya, Jasper and others
BioCentury | Nov 1, 2023
Deals
Nov. 1 Quick Takes: AZ takes stake in Cellectis, eyes 25 targets in deal
Plus: RTW acquiring Arix Bioscience, and updates from Aldeyra, AbbVie, Silence, Lilly, Sitryx and more
BioCentury | Aug 3, 2023
Deals
Novartis and Ionis aim for best in class with latest Lp(a) deal
As new entrants join Lp(a) competition, Novartis and Ionis are looking beyond the first-mover advantage of Phase III candidate pelacarsen
BioCentury | Jun 16, 2023
Data Byte
Cardiovascular target Lp(a) attracts another pharma in Lilly
With Lilly/Verve deal, three large biopharmas are now in the small but growing Lp(a) pipeline
BioCentury | Apr 11, 2023
Management Tracks
Legend hires Koneru as CMO
Plus: Erasca promotes Morris, Lovejoy and updates from Poseida, Mithra, Tune, Cellarity and more
BioCentury | Mar 28, 2023
Management Tracks
New strategy heads at Genmab and Codagenix
Plus: OncoVerity names Colao CEO and Smith CMO, and updates from Silence, Mannkind, Immuneering and more
BioCentury | Feb 7, 2023
Management Tracks
Okamura to lead Astellas
Plus: Myers at the helm of Viridian, and updates from Novartis,
BioCentury | Sep 20, 2022
Management Tracks
Luo joins Everest as CEO
Plus Hitchcock named CSO at Takeda, and updates from Viracta, Agios, Aktis and more
BioCentury | Aug 12, 2022
Finance
Week’s follow-ons, topped by Karuna, offer signs of a thaw in financings
Cerevel, others price late in the week, with bigger offerings going to companies with recent catalysts
Items per page:
1 - 10 of 151